These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25788500)

  • 1. Ceftazidime with β-lactamase inhibitor approved for complicated infections.
    Thompson CA
    Am J Health Syst Pharm; 2015 Apr; 72(7):511. PubMed ID: 25788500
    [No Abstract]   [Full Text] [Related]  

  • 2. Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic.
    Med Lett Drugs Ther; 2015 May; 57(1469):79-80. PubMed ID: 25989198
    [No Abstract]   [Full Text] [Related]  

  • 3. A β-lactamase inhibitor revival provides new hope for old antibiotics.
    Garber K
    Nat Rev Drug Discov; 2015 Jul; 14(7):445-7. PubMed ID: 26129790
    [No Abstract]   [Full Text] [Related]  

  • 4. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 5. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
    Davido B; Fellous L; Lawrence C; Maxime V; Rottman M; Dinh A
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630191
    [No Abstract]   [Full Text] [Related]  

  • 7. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia.
    Algwizani A; Alzunitan M; Alharbi A; Alsaedy A; Aljohani S; Alalwan B; Gramish J; Alothman A
    J Infect Public Health; 2018; 11(6):793-795. PubMed ID: 29706317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
    King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First case of ceftazidime/avibactam administration in home care. ESBL producing Klebsiella pneumoniae bacteremia.
    Torres-Del-Pliego E; Delgado-Mejía E; Gil-Alonso L; Del Mar-Periáñez-Párraga L
    Enferm Infecc Microbiol Clin; 2017 May; 35(5):322-323. PubMed ID: 27712848
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
    Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW
    Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.
    Alidjanov JF; Fritzenwanker M; Hoffman I; Wagenlehner FM
    Future Microbiol; 2017 Jun; 12():655-670. PubMed ID: 28338347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
    Li J; Lovern M; Riccobene T; Carrothers TJ; Newell P; Das S; Talley AK; Tawadrous M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa.
    Xipell M; Bodro M; Marco F; Losno RA; Cardozo C; Soriano A
    Int J Antimicrob Agents; 2017 Feb; 49(2):266-268. PubMed ID: 27979500
    [No Abstract]   [Full Text] [Related]  

  • 17. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.
    Pogue JM; Bonomo RA; Kaye KS
    Clin Infect Dis; 2019 Jan; 68(3):519-524. PubMed ID: 30020449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empowering Older Antibiotics.
    Wright GD
    Cell; 2016 Oct; 167(2):301. PubMed ID: 27716499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.